TpoR

TpoR製品

All (10)
TpoR活性剤(2)
TpoR作動薬(4)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S2229	Eltrombopag Olamine	Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).	J Mol Cell Biol, 2023, 15(3)mjad017 J Pers Med, 2022, 12(2)258 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S4502	Eltrombopag	Eltrombopag (SB-497115), a member of the biarylhydrazone class, is a nonpeptide agonist of the thrombopoietin receptor (TpoR), used to treat chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).	Hemasphere, 2023, 7(6):e906 Am J Cancer Res, 2022, 12(6):2697-2710 Blood Adv, 2021, bloodadvances.2021004207
S6624	Avatrombopag	Avatrombopag (AKR-501,E5501,YM477) is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation.
E1352^New	Butyzamide	Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia.
E4969^New	Avatrombopag hydrochloride	Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).
S6988	Lusutrombopag	Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).
S2229	Eltrombopag Olamine	Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).	J Mol Cell Biol, 2023, 15(3)mjad017 J Pers Med, 2022, 12(2)258 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S6624	Avatrombopag	Avatrombopag (AKR-501,E5501,YM477) is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation.
E4969^New	Avatrombopag hydrochloride	Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).
S6988	Lusutrombopag	Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).
S4502	Eltrombopag	Eltrombopag (SB-497115), a member of the biarylhydrazone class, is a nonpeptide agonist of the thrombopoietin receptor (TpoR), used to treat chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).	Hemasphere, 2023, 7(6):e906 Am J Cancer Res, 2022, 12(6):2697-2710 Blood Adv, 2021, bloodadvances.2021004207
E1352^New	Butyzamide	Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia.
S2229	Eltrombopag Olamine	Eltrombopag Olamine is a member of the biarylhydrazone class, which is a nonpeptide agonist of the thrombopoietin receptor (TpoR).	J Mol Cell Biol, 2023, 15(3)mjad017 J Pers Med, 2022, 12(2)258 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S6624	Avatrombopag	Avatrombopag (AKR-501,E5501,YM477) is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation.
E4969^New	Avatrombopag hydrochloride	Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).
S6988	Lusutrombopag	Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).
E1352^New	Butyzamide	Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia.
E4969^New	Avatrombopag hydrochloride	Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).
E4969^New	Avatrombopag hydrochloride	Avatrombopag hydrochloride(AKR-501 hydrochloride, YM477 hydrochloride) is an orally administered second generation agonist of Thrombopoietin receptor(TpoR) with an EC50 value of 3.3 nM. It is used in the treatment of primary chronic immune thrombocytopenia (ITP).

TpoR阻害剤の選択性比較